R&D refund will help support MSC trial
Stem cell company Cynata Therapeutics (ASX:CYP) has received an R&D Tax Incentive refund of $932,580.65 for the 2014–15 financial year. The tax incentive is an Australian Government program under which companies receive cash refunds of 45% of eligible expenditure on research and development.
Cynata CEO Dr Ross Macdonald said the refund “extends our operating runway at a time when we plan to soon commence the clinical trial of our first proprietary Cymerus mesenchymal stem cell (MSC) product, CYP-001”. CYP-001 was last month confirmed by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to be suitable for the company’s Phase 1 clinical trial in patients with graft versus host disease.
Cynata Therapeutics (ASX:CYP) shares were trading 7.35% higher at $0.365 as of around 2.30 pm on Wednesday.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
